Cite
HARVARD Citation
Rensel, M. et al. (2022). Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: Analysis of aquaporin-4–immunoglobulin G–seropositive participants taking inebilizumab for ⩾4 years in the N-MOmentum trial. Multiple sclerosis. pp. 925-932. [Online].